Literature DB >> 25949876

A novel subset of B7-H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC.

Guangbo Zhang1, Haitao Huang2, Yibei Zhu3, Gehua Yu3, Xin Gao3, Yunyun Xu3, Cuiping Liu4, Jianquan Hou4, Xueguang Zhang1.   

Abstract

Myeloid-derived suppressor cells (MDSC) potently inhibit antitumor immune responses, and thereby promoti tumor progression and metastasis. However, the nature of human tumor-infiltrating MDSC remains poorly characterized. Here, we find B7-H3 is exclusively expressed on a subset of intratumoral CD14+HLA-DR-/low MDSC but absent from adjacent normal lung tissues of patients with non-small cell lung carcinoma (NSCLC). Cytokine analysis revealed that B7-H3+CD14+HLA-DR-/low MDSC (B7-H3+MDSC) produced higher levels of IL-10 and TNFα but lower levels of IL-1β and IL-6 when compared with B7-H3-CD14+HLA-DR-/low myeloid-derived suppressor cells (B7-H3-MDSC). In a murine lung cancer model, B7-H3+MDSCs were found only in the tumor microenvironment and their frequencies increased during tumor progression. Clinical data analysis indicated that a higher frequency of B7-H3+MDSCs was associated with reduced recurrence-free survival in patients with NSCLC. Taken together, we identify a novel subset of MDSCs within the tumor microenvironment that fosters tumor progression.

Entities:  

Keywords:  APC, antigen presenting cell; B7-H3; B7-H3+MDSC, B7-H3+CD14+HLA-DR−/low MDSC; B7-H3−MDSC, B7-H3−CD14+HLA-DR−/low MDSC; BM, bone marrow; DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; FACS, Fluorescence activated cell sorter; LLC, Lewis Lung Carcinoma; MDSC; MDSC, Myeloid-derived suppressor cell; NSCLC, Non-small cell lung carcinoma; RT-qPCR, real-time quantitative PCR; Treg; Tumor microenvironment; mTGFβ, membrane-bound TGFβ; non-small cell lung cancer

Year:  2015        PMID: 25949876      PMCID: PMC4404793          DOI: 10.4161/2162402X.2014.977164

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  25 in total

1.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

Authors:  Arnold H Zea; Paulo C Rodriguez; Michael B Atkins; Claudia Hernandez; Sabina Signoretti; Jovanny Zabaleta; David McDermott; David Quiceno; Amanda Youmans; Anne O'Neill; James Mier; Augusto C Ochoa
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

2.  Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.

Authors:  Taku Fujimura; Sabine Ring; Viktor Umansky; Karsten Mahnke; Alexander H Enk
Journal:  J Invest Dermatol       Date:  2011-12-22       Impact factor: 8.551

3.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

4.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

5.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

Authors:  Bo Huang; Ping-Ying Pan; Qingsheng Li; Alice I Sato; David E Levy; Jonathan Bromberg; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 7.  The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?

Authors:  Sven Brandau; Katrin Moses; Stephan Lang
Journal:  Semin Cancer Biol       Date:  2013-02-28       Impact factor: 15.707

8.  Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.

Authors:  Chien-Ying Liu; Yu-Min Wang; Chih-Liang Wang; Po-Hao Feng; How-Wen Ko; Yun-Hen Liu; Yi-Cheng Wu; Yen Chu; Fu-Tsai Chung; Chih-Hsi Kuo; Kang-Yun Lee; Shu-Min Lin; Horng-Chyuan Lin; Chun-Hua Wang; Chih-Teng Yu; Han-Pin Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

9.  Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.

Authors:  Alena Gros; Simon Turcotte; John R Wunderlich; Mojgan Ahmadzadeh; Mark E Dudley; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2012-07-26       Impact factor: 12.531

10.  TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Authors:  Xin Gao; Yibei Zhu; Gang Li; Haitao Huang; Guangbo Zhang; Fengming Wang; Jing Sun; Qianting Yang; Xueguang Zhang; Binfeng Lu
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  18 in total

Review 1.  Myeloid Cells and Chronic Liver Disease: a Comprehensive Review.

Authors:  Min Lian; Carlo Selmi; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

2.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

3.  Interplay between immune cells in lung cancer: beyond T lymphocytes.

Authors:  Juan-Manuel Hernandez-Martinez; Edgar Vergara; Edgar Montes-Servín; Oscar Arrieta
Journal:  Transl Lung Cancer Res       Date:  2018-12

4.  Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Authors:  Lillian Sun; Paul E Clavijo; Yvette Robbins; Priya Patel; Jay Friedman; Sarah Greene; Rita Das; Chris Silvin; Carter Van Waes; Lucas A Horn; Jeffrey Schlom; Claudia Palena; Dean Maeda; John Zebala; Clint T Allen
Journal:  JCI Insight       Date:  2019-04-04

5.  Functional analysis of CD14+HLA-DR-/low myeloid-derived suppressor cells in patients with lung squamous cell carcinoma.

Authors:  Yun Chen; Guichang Pan; Dongbo Tian; Yifei Zhang; Taoping Li
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

6.  Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells.

Authors:  Shouheng Lin; Xuchao Zhang; Guohua Huang; Lin Cheng; Jiang Lv; Diwei Zheng; Simiao Lin; Suna Wang; Qiting Wu; Youguo Long; Baiheng Li; Wei Wei; Pentao Liu; Duanqing Pei; Yangqiu Li; Zhesheng Wen; Shuzhong Cui; Peng Li; Xiaofang Sun; Yilong Wu; Yao Yao
Journal:  Oncogene       Date:  2021-01-15       Impact factor: 9.867

7.  TREM-1low is a novel characteristic for tumor-associated macrophages in lung cancer.

Authors:  Guangbo Zhang; Hongmei Liu; Jian Huang; Siwen Chen; Xudong Pan; Haitao Huang; Ling Wang
Journal:  Oncotarget       Date:  2016-06-28

8.  Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.

Authors:  Liang Mao; Teng-Fei Fan; Lei Wu; Guang-Tao Yu; Wei-Wei Deng; Lei Chen; Lin-Lin Bu; Si-Rui Ma; Bing Liu; Yansong Bian; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  J Cell Mol Med       Date:  2017-04-11       Impact factor: 5.310

9.  Th1high in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC.

Authors:  Jian Huang; Fangrong Shen; Haitao Huang; Chunhua Ling; Guangbo Zhang
Journal:  Oncotarget       Date:  2017-02-21

Review 10.  Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer.

Authors:  Jie Ma; Huaxi Xu; Shengjun Wang
Journal:  J Immunol Res       Date:  2018-03-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.